

22TH APRIL 2009

OJSC «VEROPHARM» ANNOUNCES 2008 FINANCIAL RESULTS (AUDITED)

APRIL 22, 2008, MOSCOW – OJSC «VEROPHARM» [RTS:VRPH, MICEX:VFRM] announces 2008 financial results in accordance with the International Financial Reporting Standards (audited).

Sales

- Sales in 2008 grew by 24% and reached USD 172.9 mln in comparison with USD 139.5 mln. in 2007.
- The share of Rx drugs sales in 2008 increased to 66% as compared to 60% in 2007. The share of OTC drugs remained unchanged at 8% as compared to year before. Adhesive bandages sales share in finished goods remained unchanged at 18% as compared to year before. Portfolio of traditional drug sales also demonstrate tendency for a decrease of share in sales – the decrease from 14% to 8%.*

The sales growth in 2008 in comparison with 2007 is attributed mostly to the following factors:

- Significant growth of the top-selling drugs:
 - Bilumid (Bycalutamid) – 102%
 - Cerepro (Holina Alfostserat) – 114%
 - Irunin (Itrakanazol) – 65%
 - Taytax (Docetaxel) – 97%
 - Xilen (Xylometazoline) – 37%
 - Slabilen (Sodium picosulfate) – 75%
 - Motilak (Domperidone) – 28%
 - Poludan (Poly-A & Poly-U) – 23%
- Launch of new products in 2008, sales of which reached 3.5% of Company's sales: Vero-Anastrozol (Anastrozol); Vero-Kladribin (Klaritromicine); B-Xicam (Meloxicam); Adepress, (Paroxetin); Spiramycin-Vero (Spiramycin); Siozam (Citalopram); Vero-Amiodaron (Amiodaron).



- OJSC “Veropharm” sales in the 2008 FRP program amounted to USD 4.2 mln which makes 2% sales of the Company.*

Profit

- In 2008 the gross profit of OJSC “Veropharm” increased by 31% and reached USD 113.9 mln compared to USD 86.7 mln in 2007. Gross margin increased to 65.9% as compared to 62.2% in 2007.
- Gross margin of finish goods in 2008 66.1% against 62.3% in 2007. The increase of the gross margin materialized in the following product segments: Rx drugs - from 71.% to 73.8%; OTC drugs – from 57.6% to 68.8%, adhesive bandages - from 55.5% to 56.0%. The gross margin in the traditional products – from 36.0% to 21.0%.
- In 2008 EBITDA increased by 24% and reached USD 52.5 mln which makes 30,4% of Company’s sales.
- The net profit grew by 33% to USD 36.9 mln which makes 21.3 % of Company’s sales (an increase of 1,4 % in comparison with 2007).

Gross profit and finished goods sales structure, OJSC “Veropharm”:

<i>USD mln</i>	2008	2007	Change, %
RX			
Sales	113.5	83.3	36%
Gross Profit	83.7	59.3	41%
Gross Margin, %	73.8%	71.2%	2.6%
OTC			
Sales	15.1	11.8	28%
Gross Profit	10.4	6.8	53%
Gross Margin, %	68.8%	57.6%	11.2%
Adhesive bandages			
Sales	30.4	24.6	24%
Gross Profit	17.0	13.6	25%
Gross Margin, %	56.0%	55.5%	0.5%
Traditional drugs			
Sales	13.4	19.4	-31%
Gross Profit	2.8	7.0	-60%
Gross Margin, %	21.0%	36.0%	-15.0%
Total, finished goods			
Sales	172.4	139.1	24%
Gross Profit	113.9	86.7	31%
Gross Margin, %	66.1%	62.3%	3.8%

Facilities investments

- The modernization and production facilities' upgrade of the Company's core production assets amounted to USD 5.0 mln.

Debt

- As of the end of 2007 the debt of OJSC "Veropharm" amounted to USD 24.5 mln that represents less than 20 % of net assets.

*-according to management accounts

For further information please call OJSC "Veropharm":

Maksutova Nadiya,
Chief Financial Officer

maksutova.nadiya@veropharm.ru
tel. (+7495) 792 53 30

Or web-site of the Company

www.veropharm.ru

Notes to the Editor:

VEROPHARM is one of the largest Russian pharmaceutical producers. Shares of the Company are listed on RTS (ticker: VRPH) and are also traded at MICEX (ticker: VFRM). Market capitalization as of April 20, 2009 totaled \$181,5 million (according to RTS).

The charter capital of the Company totals 10 million ordinary shares. VEROPHARM is the market leader in Russia for production of plasters and oncological medicines. The Company's production facilities comprise 3 pharmaceutical plants in Belgorod, Voronezh and Pokrov. The Company's product portfolio includes more than 400 items. VEROPHARM employs about 2,500 people.

According to CMR "Pharmexpert", as of the end of 2008 Veropharm ranked 5th among Russian pharmaceutical producers in production volume terms.

According to DSM-Group, as of the end of 2008 companies Veropharm took 20th position in hospital market in volume terms.

According to RMBC, as of the end of 2008 compared to 2007 Veropharm ranked 4th position in overall ranking of oncology drugs producers. As far as oncology drug producers ranking in pack terms concerned, Veropharm maintained its leading position.



THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION, AND IS NOT AN OFFER TO SELL, OR AN INVITATION TO MAKE OFFERS TO PURCHASE, ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document may include statements that are "forward-looking statements", including future operating results of the Company. These forward-looking statements involve risk and uncertainty regarding implementation of future activities. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. The Company undertakes no obligation to change these statements to reflect actual results.

This document does not contain a public offer to purchase securities in the US. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.



OJSC "VEROPHARM"

CONSOLIDATED INCOME STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2008

(in thousands of US Dollars)

	<u>2 008</u>	<u>2 007</u>
REVENUE	172 864	139 491
COST OF SALES	(58 949)	(52 781)
GROSS PROFIT	<u>113 915</u>	<u>86 710</u>
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	(66 880)	(47 272)
SHARE BASED PAYMENTS EXPENSE	805	(924)
OPERATING INCOME	<u>47 840</u>	<u>38 514</u>
INTEREST EXPENSE	(2 410)	(2 627)
FOREIGN CURRENCY EXCHANGE GAIN/(LOSS)	<u>(2 365)</u>	<u>812</u>
PROFIT BEFORE INCOME TAX EXPENSE	43 065	36 699
INCOME TAX EXPENSE	(6 166)	(8 973)
NET PROFIT	<u>36 899</u>	<u>27 726</u>



OJSC “VEROPHARM”

CONSOLIDATED BALANCE SHEET

AT 31 DECEMBER 2008

(in thousands of US Dollars)

	<u>2 008</u>	<u>2 007</u>
ASSETS		
NON-CURRENT ASSETS:		
Property, plant & equipment, net	27 405	31 776
Goodwill	9 779	11 705
Intangible assets	1 792	2 194
Total non-current assets	<u>38 976</u>	<u>45 675</u>
CURRENT ASSETS:		
Inventories	19 289	22 283
Trade receivables	118 717	93 949
Other receivables and prepaid expenses	6 519	5 935
Loans receivables	4 708	4 823
Cash	49	562
Total current assets	<u>149 282</u>	<u>127 552</u>
TOTAL ASSETS	<u><u>188 258</u></u>	<u><u>173 227</u></u>
EQUITY AND LIABILITIES		
EQUITY:		
Share capital	365	365
Other reserves	(11 125)	14 537
Retained earnings	144 573	107 674
Total equity	<u>133 813</u>	<u>122 576</u>
NON-CURRENT LIABILITIES:		
Long-term borrowings	1 850	10 292
Share-based payment liability	-	963
Long-term portion of obligations under finance leases	227	561
Deferred tax liabilities	3 031	3 797
Other liabilities	-	1 418
Total non-current liabilities	<u>5 108</u>	<u>17 031</u>
CURRENT LIABILITIES:		
Short-term borrowings	22 637	13 662
Trade payables	9 874	7 628
Tax payables	6 361	5 785
Other payables	9 706	5 422
Current portion of obligations under finance leases	759	1 123
Total current liabilities	<u>49 337</u>	<u>33 620</u>
TOTAL LIABILITIES	<u><u>54 445</u></u>	<u><u>50 651</u></u>
TOTAL EQUITY AND LIABILITIES	<u><u>188 258</u></u>	<u><u>173 227</u></u>



OJSC "VEROPHARM"

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2008

(in thousands of US Dollars)

	<u>2008</u>	<u>2007</u>
OPERATING ACTIVITIES:		
Profit before income tax expense	36 899	27 726
Adjustments for		
Income tax	6 166	8 973
Finance costs, net	2 410	2 627
Depreciation and amortization	4 618	3 557
Loss on disposal of property, plant and equipment	197	103
Loss on disposal of other intangible assets	3	48
Change in allowance for doubtful debts	549	(1 664)
Change in inventory obsolescence allowance	(140)	582
Share based payment expense	(805)	924
Foreign currency exchange loss/(gain), net	2 365	(812)
Other	-	15
Profit before movements in working capital	<u>52 262</u>	<u>42 079</u>
Movements in working capital:		
Inventories	(575)	(3 182)
Trade receivables	(48 100)	(27 861)
Other receivables and prepaid expenses	(2 706)	(754)
Trade payables	4 139	668
Other payables	7 054	4 087
Cash generated from operations	<u>12 074</u>	<u>15 037</u>
Interest paid	(2 415)	(2 204)
Income taxes paid	(9 543)	(7 829)
Net cash generated by operating activities	<u>116</u>	<u>5 004</u>
INVESTING ACTIVITIES:		
Purchases of property, plant, equipment	(5 090)	(5 705)
Proceeds from disposal of property, plant, equipment	60	59
Purchase of intangible assets	(775)	(666)
Net cash used in investing activities	<u>(5 805)</u>	<u>(6 312)</u>
FINANCING ACTIVITIES:		
Proceeds from borrowings	49 234	40 509
Repayment of borrowings	(43 944)	(38 885)
Net cash generated by financing activities	<u>5 290</u>	<u>1 624</u>
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	(399)	316
CASH AND CASH EQUIVALENTS, beginning of period	562	215
Effect of translation to presentation currency	(114)	31
CASH AND CASH EQUIVALENTS, end of period	<u>49</u>	<u>562</u>